- SPANNR
- Posts
- Issue #33
Issue #33
Issue #33
January 12, 2023 | Issue #33
Good evening. In breaking news (literally hours ago), Dr. David Sinclair, a professor of genetics at Harvard Medical School, just published an enlightening study that will likely have industry heads spinning. It’s been 13 years in the making, but without getting ahead of ourselves, Sinclair and his colleagues may have unlocked a key milestone in learning how to reverse aging. While there's still much to decipher and unpack, you can see a quick presentation/explainer of the results here.In this week's newsletter:📌 Longevity Biotech 101📢 This week's funding announcements✨ Business news & weekend reading material
An Introduction to the Longevity Industry: What it is, Growth & Companies
As the industry of longevity continues to expand and evolve in 2023 (see the 2022 milestones here), Spannr is dedicated to providing our readers with a comprehensive understanding of the field and all the exciting possibilities it holds.To that end, we invite you to consider our latest post as an introduction to the world of longevity, where we dive into the size and growth of the industry, examine the various sectors and components that make it up, and highlight some of the leading companies and players in the field.Continue reading as we explore the cutting-edge science, technology, and companies that have us eagerly anticipating the future of human longevity.
For what it's worth, this guide serves as a great resource for friends and family who may be unaware of the emerging longevity biotech sector and for those who would like to get a better understanding of the science and technology that is shaping the future of our society, economy, and healthcare. So please – share, pass it around, or bookmark – as this post will be continuously updated!
The Retinal Degeneration Fund invests in a $78 million Series B for Perceive Biotherapeutics, a biotechnology company developing novel treatments, leading with a gene therapy candidate for dry age-related macular degeneration
MPC Therapeutics, a Swiss biotechnology company focused on metabolism and rejuvenation, announced the closing of its CHF1.5 million seed-funding round
Palvella Therapeutics announces Series D Financing of Up to $37.7 million to accelerate late-stage development and support commercialization of novel therapies for serious, rare genetic skin diseases
NewLimit Provides December 2022 Progress Update
Gero Entered a Research Collaboration with Pfizer to Discover Potential Targets for Fibrotic Diseases
Longevity Education Hub announces the setup of national chapters and expands longevity medicine courses to Portuguese and Spanish
Cyclarity Therapeutics Plans Human Clinical Trials in the UK
Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones
Curative Biotechnology Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study
U.S. FDA Gives Green Light to Leqembi, aka Lecanemab (Alzforum)
Mapping the Longevity Industry from a VC Perspective (Sergey Jakimov)
Scientists say they gene hacked mice to double remaining lifespan (Futurism)
Head Transplant Surgeon Claims Human Brain Transplants Are 'Technically Feasible' (Vice)
U.S. Cancer Death Rate Has Dropped by a Third Since 1991 (WSJ)
Here are the states with the longest life expectancy (The Hill)
Ants Live 10 Times Longer by Altering Their Insulin Responses (QuantaMagazine)
What time you exercise may be more important than the workout itself (Methuselah Foundation)
FDA Increasingly Halting Human Trials as Companies Pursue Risky, Cutting-Edge Drugs (WSJ)
Performance:
Latest Price: $123.827d-Return: 13.04% Market Cap: $12.69b